Physician profile
Lawrence A Mora
NPI 1205851615
$5,809.24
in general payments reported to CMS, 2019-2025
42 companies · $970 in 2025
The $970 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $219 · 2021: $797 · 2022: $1,171 · 2023: $1,069 · 2024: $1,032 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,056 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,056.19 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $766.30 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $597.26 | 2019-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $536.86 | 2019-2023 | |
| Amgen INC. | $395.50 | 2020-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.58 | 2019-2025 | Xifaxan |
| Alkermes, INC. | $331.26 | 2020-2025 | Vivitrol, Vivitrol |
| Abbvie INC. | $300.16 | 2019-2025 | |
| Indivior INC. | $272.54 | 2024-2025 | Sublocade |
| Glaxosmithkline, LLC. | $190.43 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Almatica Pharma LLC | $189.76 | 2022-2025 | Loreev Xr, Teriparatide |
| Novo Nordisk INC | $171.48 | 2022-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $158.18 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $156.03 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $133.75 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.25 | 2021-2024 | Jardiance, Tradjenta, Stiolto Respimat |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.